Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

2,052 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Neurological adverse effects associated with anti-PD1 antibodies alone or in combination with ipilimumab: a multicenter case series.
Smith JL, Menzies AM, Cohen JV, Mut-Lloret M, Ozgun A, Spain L, Park J, Quach HT, Pallan L, McQuade J, Feng S, Sandhu S, Atkinson V, Tsai K, Long GV, Larkin J, Eroglu Z, Johnson DB, Sullivan R, Herkes GK, Henderson A, Carlino MS. Smith JL, et al. Melanoma Res. 2022 Sep 23. doi: 10.1097/CMR.0000000000000825. Online ahead of print. Melanoma Res. 2022. PMID: 36164923
Targeting FOLR1 in high-risk CBF2AT3-GLIS2 Pediatric AML with STRO-002 FOLR1-Antibody-Drug Conjugate.
Loeb KR, Le QH, Tang T, Castro SK, Pardo L, McKay CN, Perkins L, Smith JL, Kirkey DC, Abrahams C, Bedard K, Molina A, Eidenschink Brodersen L, Loken MR, Tarlock K, Meshinchi S. Loeb KR, et al. Among authors: smith jl. Blood Adv. 2022 Sep 23:bloodadvances.2022008503. doi: 10.1182/bloodadvances.2022008503. Online ahead of print. Blood Adv. 2022. PMID: 36149945 No abstract available.
CBFA2T3-GLIS2 model of pediatric acute megakaryoblastic leukemia identifies FOLR1 as a CAR T cell target.
Le Q, Hadland B, Smith JL, Leonti A, Huang BJ, Ries R, Hylkema TA, Castro S, Tang TT, McKay CN, Perkins L, Pardo L, Sarthy J, Beckman AK, Williams R, Idemmili R, Furlan S, Ishida T, Call L, Srivastava S, Loeb AM, Milano F, Imren S, Morris SM, Pakiam F, Olson JM, Loken MR, Eidenschink Brodersen L, Riddell SR, Tarlock K, Bernstein ID, Loeb KR, Meshinchi S. Le Q, et al. Among authors: smith jl. J Clin Invest. 2022 Sep 22:e157101. doi: 10.1172/JCI157101. Online ahead of print. J Clin Invest. 2022. PMID: 36136600 Free article.
2,052 results